Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Sara A. Hurvitz, MD, on Early-Stage Breast Cancer: How HER2 Testing May Influence Neoadjuvant Therapy

Posted: Monday, July 22, 2019

Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, discusses the influence of HER2 test results on the decision to recommend a neoadjuvant strategy in patients with early-stage breast cancer, based on the findings of the KRISTINE trial.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.